Savonitto S, Ardissiono D, Egstrup K, Rasmussen K, Bae E A, Omland T, Schjelderup-Mathiesen P M, Marraccini P, Wahlqvist I, Merlini P A, Rehnqvist N
Seconda Divisione Cardiologica, Ospedale Niguarda Ca' Granda, Milan, Italy.
J Am Coll Cardiol. 1996 Feb;27(2):311-6. doi: 10.1016/0735-1097(95)00489-0.
This study was designed to investigate whether combination therapy with metoprolol and nifedipine provides a greater anti-ischemic effect than does monotherapy in individual patients with stable angina pectoris.
Combination therapy with a beta-adrenergic blocking agent (which reduces myocardial oxygen consumption) and a dihydropyridine calcium antagonist (which increases coronary blood flow) is a logical approach to the treatment of stable angina pectoris. However, it is not clear whether, in individual patients, this combined therapy is more effective than monotherapy.
Two hundred eighty patients with stable angina pectoris were enrolled in a double-blind trial in 25 European centers. Patients were randomized (week 0) to metoprolol (controlled release, 200 mg once daily) or nifedipine (Retard, 20 mg twice daily) for 6 weeks; placebo or the alternative drug was then added for a further 4 weeks. Exercise tests were performed at weeks 0, 6 and 10.
At week 6, both metoprolol and nifedipine increased the mean exercise time to 1-mm ST segment depression in comparison with week 0 (both p < 0.01); metoprolol was more effective than nifedipine (p < 0.05). At week 10, the groups randomized to combination therapy had a further increase in time to 1-mm ST segment depression (p < 0.05 vs. placebo). Analysis of the results in individual patients revealed that 7 (11%) of 63 patients adding nifedipine to metoprolol and 17 (29%) of 59 patients (p < 0.0001) adding metoprolol to nifedipine showed an increase in exercise tolerance that was greater than the 90th percentile of the distribution of the changes observed in the corresponding monotherapy + placebo groups. However, among these patients, an additive effect was observed only in 1 (14%) of the 7 patients treated with metoprolol + nifedipine and in 4 (24%) of the 17 treated with nifedipine + metoprolol.
The mean additive anti-ischemic effect shown by combination therapy with metoprolol and nifedipine in patients with stable angina pectoris is not the result of an additive effect in individual patients. Rather, it may be attributed to the recruitment by the second drug of patients not responding to monotherapy.
本研究旨在调查美托洛尔与硝苯地平联合治疗相较于单药治疗,对稳定型心绞痛个体患者是否具有更大的抗缺血作用。
β-肾上腺素能阻滞剂(可降低心肌耗氧量)与二氢吡啶类钙拮抗剂(可增加冠状动脉血流量)联合治疗是治疗稳定型心绞痛的合理方法。然而,在个体患者中,这种联合治疗是否比单药治疗更有效尚不清楚。
280例稳定型心绞痛患者在25个欧洲中心参与了一项双盲试验。患者在第0周随机分组,接受美托洛尔(控释片,每日一次,200毫克)或硝苯地平(缓释片,每日两次,20毫克)治疗6周;然后添加安慰剂或另一种药物再治疗4周。在第0、6和10周进行运动试验。
在第6周时,与第0周相比,美托洛尔和硝苯地平均使平均运动时间延长至ST段压低1毫米(两者p<0.01);美托洛尔比硝苯地平更有效(p<0.05)。在第10周时,随机接受联合治疗的组至ST段压低1毫米的时间进一步延长(与安慰剂相比,p<0.05)。对个体患者结果的分析显示,63例在美托洛尔基础上加用硝苯地平的患者中有7例(11%),59例在硝苯地平基础上加用美托洛尔的患者中有17例(29%)(p<0.0001),其运动耐量的增加大于相应单药治疗加安慰剂组观察到的变化分布的第90百分位数。然而,在这些患者中,仅在7例接受美托洛尔+硝苯地平治疗的患者中有1例(14%)以及17例接受硝苯地平+美托洛尔治疗的患者中有4例(24%)观察到相加效应。
美托洛尔与硝苯地平联合治疗对稳定型心绞痛患者显示出的平均相加抗缺血作用并非个体患者相加效应的结果。相反,这可能归因于第二种药物招募了对单药治疗无反应的患者。